251 related articles for article (PubMed ID: 20961967)
1. Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus.
Park JS; Cho MH; Nam JS; Yoo JS; Ahn CW; Cha BS; Kim KR; Lee HC
Eur J Endocrinol; 2011 Jan; 164(1):69-74. PubMed ID: 20961967
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial.
Esteghamati A; Afarideh M; Feyzi S; Noshad S; Nakhjavani M
Diabetes Metab Syndr; 2015; 9(4):258-65. PubMed ID: 25450818
[TBL] [Abstract][Full Text] [Related]
3. The comparative effect of pioglitazone and metformin on serum osteoprotegerin, adiponectin and intercellular adhesion molecule concentrations in patients with newly diagnosed type 2 diabetes: a randomized clinical trial.
Esteghamati A; Azizi R; Ebadi M; Noshad S; Mousavizadeh M; Afarideh M; Nakhjavani M
Exp Clin Endocrinol Diabetes; 2015 May; 123(5):289-95. PubMed ID: 25607338
[TBL] [Abstract][Full Text] [Related]
4. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
5. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
Sharma PK; Bhansali A; Sialy R; Malhotra S; Pandhi P
Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
[TBL] [Abstract][Full Text] [Related]
6. Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.
Derosa G; Mereu R; Salvadeo SA; D'Angelo A; Ciccarelli L; Piccinni MN; Ferrari I; Gravina A; Maffioli P; Cicero AF
Intern Med; 2009; 48(5):265-71. PubMed ID: 19252346
[TBL] [Abstract][Full Text] [Related]
7. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
Kadoglou NP; Kapelouzou A; Tsanikidis H; Vitta I; Liapis CD; Sailer N
Exp Clin Endocrinol Diabetes; 2011 Feb; 119(2):63-8. PubMed ID: 21031343
[TBL] [Abstract][Full Text] [Related]
8. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.
Sathyanarayana P; Jogi M; Muthupillai R; Krishnamurthy R; Samson SL; Bajaj M
Obesity (Silver Spring); 2011 Dec; 19(12):2310-5. PubMed ID: 21660077
[TBL] [Abstract][Full Text] [Related]
9. The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus.
Erdem G; Dogru T; Tasci I; Bozoglu E; Muhsiroglu O; Tapan S; Ercin CN; Sonmez A
Diabetes Res Clin Pract; 2008 Nov; 82(2):214-8. PubMed ID: 18778865
[TBL] [Abstract][Full Text] [Related]
10. The ratio of leptin to adiponectin can be used as an index of insulin resistance.
Oda N; Imamura S; Fujita T; Uchida Y; Inagaki K; Kakizawa H; Hayakawa N; Suzuki A; Takeda J; Horikawa Y; Itoh M
Metabolism; 2008 Feb; 57(2):268-73. PubMed ID: 18191059
[TBL] [Abstract][Full Text] [Related]
11. Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study.
Hanefeld M; Pfützner A; Forst T; Kleine I; Fuchs W
Cardiovasc Diabetol; 2011 Jul; 10():65. PubMed ID: 21756323
[TBL] [Abstract][Full Text] [Related]
12. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Derosa G; Maffioli P; Ferrari I; Mereu R; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Salvadeo SA
Horm Metab Res; 2010 Aug; 42(9):663-9. PubMed ID: 20560108
[TBL] [Abstract][Full Text] [Related]
13. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
[TBL] [Abstract][Full Text] [Related]
14. Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome.
Fujitaka K; Otani H; Jo F; Jo H; Nomura E; Iwasaki M; Nishikawa M; Iwasaka T
Endocr J; 2011; 58(6):425-32. PubMed ID: 21498915
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.
Schernthaner G; Matthews DR; Charbonnel B; Hanefeld M; Brunetti P;
J Clin Endocrinol Metab; 2004 Dec; 89(12):6068-76. PubMed ID: 15579760
[TBL] [Abstract][Full Text] [Related]
16. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin.
Derosa G; Fogari E; Cicero AF; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Gravina A; Ferrari I; Fogari R
Hypertens Res; 2007 May; 30(5):387-94. PubMed ID: 17587750
[TBL] [Abstract][Full Text] [Related]
17. Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load.
Derosa G; Cicero AF; Fogari E; D'Angelo A; Bianchi L; Maffioli P
Horm Metab Res; 2011 Jun; 43(7):505-12. PubMed ID: 21590648
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes.
Eguchi K; Tomizawa H; Ishikawa J; Hoshide S; Numao T; Fukuda T; Shimada K; Kario K
Hypertens Res; 2007 Jan; 30(1):23-30. PubMed ID: 17460368
[TBL] [Abstract][Full Text] [Related]
19. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes.
Martens FM; Visseren FL; de Koning EJ; Rabelink TJ
J Cardiovasc Pharmacol; 2005 Dec; 46(6):773-8. PubMed ID: 16306801
[TBL] [Abstract][Full Text] [Related]
20. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]